Why are patients with chronic myeloid leukaemia (non-)adherent?

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

(2012) F Efficace et al.   BRITISH JOURNAL OF CANCER

Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia

(2011) Prasanth Ganesan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study

(2011) Sofia Jönsson et al.   ANNALS OF HEMATOLOGY

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

(2011) A. R. Ibrahim et al.   BLOOD

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed

(2010) Lina Eliasson et al.   LEUKEMIA RESEARCH

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

Patient adherence and persistence with oral anticancer treatment

(2009) K. Ruddy et al.   CA-A CANCER JOURNAL FOR CLINICIANS